ConvaTec Group PLC (CTEC) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally.
Total Revenue Chart for ConvaTec Group PLC
ConvaTec Group PLC (CTEC) revenue for FY2025 was GBP 2.5B, a 8.8% change from FY2024. ConvaTec Group PLC's revenue grew from GBP 1.7B in 2013 to GBP 2.5B in 2025 (46.4% over 12 years). Earnings per share moved from GBP -0.09 in 2013 to GBP 0.03 in 2022. Revenue compound annual growth rate: 5-year CAGR of 5.6%, 10-year CAGR of 4.2%.
Total Revenue (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £4.48B
- Implied Share Price
- £2.30
- Enterprise Value
- £5.79B
- Revenue (TTM)
- £2.49B
- EBITDA
- £582.00M
- Profit Margin
- 4.98%
- Trailing P/E
- 45.92
- Forward P/E
- 15.75
- Price/Book (MRQ)
- 4.30
- Price/Sales (TTM)
- 1.80
- EV/EBITDA
- 17.25
- EV/Revenue
- 3.13
- Dividend Yield
- 3.24%
- Book Value
- £0.54
- Free Cash Flow (FY2025)
- £342.03M
- Free Cash Flow Yield
- 7.64%
Snapshot as of 15th August 2026 — not point-in-time controlled, may lag the live market by a few days.